Anti-CTLA4 treatment was associated with a coordinated “spike” in effector/memory (CD44highCD62L−) CD8 T cells around day 14 (Figure 5a,b top row), following treatment completion (day 12) and coinciding with the start of tumor rejection. Here, CD8A is linked to neoplasm.